Scynexis (SCYX) Operating Expenses (2013 - 2026)
Scynexis' (SCYX) quarterly Operating Expenses came in at $8.0 million in Q2 2026, down 26.68% on a YoY basis from $10.9 million in Q2 2025, and down 52.71% quarter-over-quarter from $16.9 million in Q1 2026.
Analysis
Scynexis (SCYX) Operating Expenses (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Operating Expenses for 14 consecutive years, with $8.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Expenses fell 26.68% year-over-year to $8.0 million; the trailing twelve-month figure through Jun 2026 stood at $41.8 million (up 5.05% YoY), and the FY2025 full-year result was $36.7 million, down 10.25% from the prior year.
- Operating Expenses fell to $8.0 million in Q2 2026 per SCYX's latest filing, from $16.9 million in the prior quarter.
- Across five years, Operating Expenses topped out at $28.9 million in Q4 2023 and bottomed at $8.0 million in Q2 2026.
- Historically, Operating Expenses has averaged $14.5 million across 5 years, with a median of $11.4 million in 2023.
- The sharpest annual moves came in 2024 and 2026: Operating Expenses slumped 68.71% in 2024, then jumped 91.03% in 2026.
- Over 5 years, Operating Expenses stood at $24.0 million in 2022, then gained by 20.23% to $28.9 million in 2023, then plunged by 68.71% to $9.0 million in 2024, then decreased by 10.02% to $8.1 million in 2025, then slipped by 1.42% to $8.0 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $8.0 million, $16.9 million, and $8.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 367.83 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 8.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.01 Mn |
| Mar 31, 2026 | 16.94 Mn |
| Dec 31, 2025 | 8.13 Mn |
| Sep 30, 2025 | 8.74 Mn |
| Jun 30, 2025 | 10.93 Mn |
| Mar 31, 2025 | 8.87 Mn |
| Dec 31, 2024 | 9.03 Mn |
| Sep 30, 2024 | 10.98 Mn |
| Jun 30, 2024 | 9.97 Mn |
| Mar 31, 2024 | 10.88 Mn |
| Dec 31, 2023 | 28.86 Mn |
| Sep 30, 2023 | 11.86 Mn |
| Jun 30, 2023 | 14.94 Mn |
| Mar 31, 2023 | 11.81 Mn |
| Dec 31, 2022 | 24.01 Mn |
| Sep 30, 2022 | 23.36 Mn |
| Jun 30, 2022 | 23.06 Mn |
| Mar 31, 2022 | 20.43 Mn |
| Dec 31, 2021 | 22.89 Mn |
| Sep 30, 2021 | 19.96 Mn |